• Eupraxia Pharmaceuticals (NASDAQ:EPRX) announced today the appointment of Robert Bazemore, Amy Pott, and Dr. Helen Thackray to its Board of Directors.
  • The company is a clinical-stage biotechnology company with a market capitalization of $426 million.
  • This announcement comes as EPRX is trading at $7.00 (+7.4%) in pre-market, rebounding from a 2.5% drop to $6.52 at the close on July 06, 2026.